Press Releases
13 November 2008 - Result of AGM
7 November 2008 - Change of NOMAD
31 October 2008 - Total voting rights
20 October 2008 - Director shareholdings
10 October 2008 - Posting of 2008 annual report
8 October 2008 - Change of Broker and Nominated Adviser Name
22 September 2008 - Research update on inhaled interferon beta programme
4 August 2008 - Director shareholdings
31 July 2008 - Preliminary results for the year ended 30 June 2008
29 July 2008 - Commencement of clinical trial
14 July 2008 - Preliminary results announcement date
23 May 2008 - Presentation of data at American Thoracic Society (ATS)
13 March 2008 - Director shareholding
12 March 2008 - Interim Results for the six months ended 31 December 2007
25 February 2008 - Interim results announcement date
11 February 2008 - Patent granted for Lung Barrier Screening Test
12 December 2007 - Research collaboration with Wayne State University
15 November 2007 - Result of AGM
12 November 2007 - Contract with Alpha Biologics
31 October 2007 - Director shareholding
28 September 2007 - Licence and supply agreement for interferon beta from Rentschler
26 September 2007 - Preliminary results for the year ended 30 June 2007
20 August 2007 - Preliminary results announcement date
17 August 2007 - AIM Rule 26
16 August 2007 - Change of adviser
28 June 2007 - Holding in Company
12 June 2007 - Successful Outcome of Phase I Clinical Study
of Inhaled Interferon Beta
20 March 2007 Holding in Company
19 March 2007 - Interim Results for the six months ended 31 December 2006
23 February 2007 - Holding in Company
13 February 2007 - Interim results announcement date
11 December 2006 - Total Voting Rights announcement
30 November 2006 - Director shareholding
15 November 2006 - Results from AGM
15 November 2006 - Novel Peptide treatment of asthma
8 November 2006 - Director shareholding
8 November 2006 - Holding in Company
18 September 2006 - 2006 Preliminary Statement
1 September 2006 - Preliminary results announcement date
14 August 2006 - Interferon lambda intellectual property licensed from Imperial Innovations
24 May 2006 - New research signals second indication for Interferon beta programme in COPD
11 April 2006 - Synairgen PLC board changes
February 2006 - Interim Results for the six months ended 31 December 2005
January 2006 - Notification of Interim Results
November 2005 - Director/PDMR Shareholding
November 2005 - Result of AGM
November 2005 - Interferon-Beta Enters Clinic
November 2005 - Change of Adviser
September 2005 - Preliminary Results for the year ended 30 June 2005
July 2005 - Holding in Company
March 2005 - Research identifies potential new therapy for asthmatics to combat colds
(Media Information)
March 2005 - Holding in Company
March 2005 - Interim Results to 31 Dec 2004
March 2005 - Collaboration with Centocor
November 2004 - Holding in Company
October 2004 - Successful £10.5 million placing
October 2004 - Intention to float on AIM
June 2004 - Collaboration with Merck
January 2004 - Collaboration with CAT
